SG Americas Securities LLC Makes New Investment in Celcuity Inc. (NASDAQ:CELC)

SG Americas Securities LLC bought a new position in shares of Celcuity Inc. (NASDAQ:CELC) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 7,995 shares of the company’s stock, valued at approximately $119,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC grew its holdings in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after buying an additional 3,930 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after buying an additional 1,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Celcuity by 7.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after buying an additional 1,600 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Celcuity by 27.7% in the 2nd quarter. Rhumbline Advisers now owns 32,464 shares of the company’s stock valued at $532,000 after buying an additional 7,049 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Performance

Shares of Celcuity stock opened at $15.61 on Friday. The firm has a market capitalization of $547.93 million, a P/E ratio of -5.62 and a beta of 0.75. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The company has a 50 day moving average price of $15.51 and a 200 day moving average price of $16.25. Celcuity Inc. has a 52 week low of $9.36 and a 52 week high of $22.19.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same quarter in the previous year, the business earned ($0.66) earnings per share. Sell-side analysts expect that Celcuity Inc. will post -2.54 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Thursday, August 15th. Leerink Partners assumed coverage on shares of Celcuity in a report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a report on Thursday, August 15th. Finally, Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $29.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.